Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 14Docetaxel 7cemiplimab 4avelumab 4Trastuzumab 4Paclitaxel 4fludarabine 3durvalumab 3atezolizumab 3Psychiatric Rehabilitation 3Nivolumab 3Methods 3Gemcitabine 3Fluorouracil 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3zimberelimab 2poly ICLC 2palbociclib 2belinostat 2amminedichloro(2-methylpyridine)platinum(II) 2Tetrahydrouridine 2Taxes 2Standard of Care 2Specimen Handling 2Sirolimus 2Radiotherapy 2Positron-Emission Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × resiquimod × Breast × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡